Bonnie Leung1, Janessa Laskin1,2, Jonn Wu2,3, Alan Bates2,4, Cheryl Ho1,2. 1. Department of Medical Oncology, BC Cancer, Vancouver, British Columbia. 2. Department of Medicine, University of British Columbia, Vancouver, British Columbia. 3. Department of Radiation Oncology, BC Cancer, Vancouver, British Columbia. 4. Department of Psychosocial Oncology, BC Cancer, Vancouver, British Columbia.
Abstract
OBJECTIVE: The Psychosocial Screen for Cancer (PSSCAN-R) questionnaire is a validated screening tool used to identify the psychosocial needs of patients with cancer. It assesses patients' perceived social supports and psychosocial needs, and the presence of symptoms of depression and anxiety. The study goals were to assess the prevalence and factors associated with distress in patients with newly diagnosed nonsmall cell lung cancer (NSCLC). METHODS: All patients with NSCLC referred to BC Cancer centers from 2011 to 2015, who completed a prospective PSSCAN-R questionnaire at the time of their first visit, were included in the study. Demographics and baseline disease characteristics were collected retrospectively. The chi-squared test, Fisher exact test, and logistical regression analysis were used to compare factors associated with the presence of distress based on sex, age, stage of disease, and performance status (PS). RESULTS: A total of 4281 NSCLC patients completed the PSSCAN-R questionnaire. Baseline characteristics: 70% were greater than or equal to 65, 50% female, 52% metastatic disease, 47% Eastern Cooperative Oncology Group (ECOG) greater than or equal to two. Patients who were female, less than 65, have metastatic disease and poor PS were more likely to report subclinical or clinical symptoms of anxiety. Symptoms of depression were associated with younger, female, poor PS patients, and social isolation. CONCLUSIONS: Newly diagnosed patients with NSCLC are likely to report clinical symptoms of anxiety and depression and have a high number of concerns in multiple psychosocial domains. Resource development for lung cancer patients should be based on their care needs with careful consideration of patients' age, gender, stage, and social situation to optimally support their psychosocial needs during treatment and follow-up.
OBJECTIVE: The Psychosocial Screen for Cancer (PSSCAN-R) questionnaire is a validated screening tool used to identify the psychosocial needs of patients with cancer. It assesses patients' perceived social supports and psychosocial needs, and the presence of symptoms of depression and anxiety. The study goals were to assess the prevalence and factors associated with distress in patients with newly diagnosed nonsmall cell lung cancer (NSCLC). METHODS: All patients with NSCLC referred to BC Cancer centers from 2011 to 2015, who completed a prospective PSSCAN-R questionnaire at the time of their first visit, were included in the study. Demographics and baseline disease characteristics were collected retrospectively. The chi-squared test, Fisher exact test, and logistical regression analysis were used to compare factors associated with the presence of distress based on sex, age, stage of disease, and performance status (PS). RESULTS: A total of 4281 NSCLCpatients completed the PSSCAN-R questionnaire. Baseline characteristics: 70% were greater than or equal to 65, 50% female, 52% metastatic disease, 47% Eastern Cooperative Oncology Group (ECOG) greater than or equal to two. Patients who were female, less than 65, have metastatic disease and poor PS were more likely to report subclinical or clinical symptoms of anxiety. Symptoms of depression were associated with younger, female, poor PS patients, and social isolation. CONCLUSIONS: Newly diagnosed patients with NSCLC are likely to report clinical symptoms of anxiety and depression and have a high number of concerns in multiple psychosocial domains. Resource development for lung cancerpatients should be based on their care needs with careful consideration of patients' age, gender, stage, and social situation to optimally support their psychosocial needs during treatment and follow-up.
Authors: Ramaswamy Govindan; Charu Aggarwal; Scott J Antonia; Marianne Davies; Steven M Dubinett; Andrea Ferris; Patrick M Forde; Edward B Garon; Sarah B Goldberg; Raffit Hassan; Matthew D Hellmann; Fred R Hirsch; Melissa L Johnson; Shakun Malik; Daniel Morgensztern; Joel W Neal; Jyoti D Patel; David L Rimm; Sarah Sagorsky; Lawrence H Schwartz; Boris Sepesi; Roy S Herbst Journal: J Immunother Cancer Date: 2022-05 Impact factor: 12.469
Authors: Carolyn J Presley; Nicole A Arrato; Sarah Janse; Peter G Shields; David P Carbone; Melisa L Wong; Ling Han; Thomas M Gill; Heather G Allore; Barbara L Andersen Journal: JCO Oncol Pract Date: 2021-05-03